Hyderabad News Desk

DelveInsight’s, “Biliary Tract Cancers Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers pipeline landscape. It covers the Biliary Tract Cancers pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Biliary Tract Cancers pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Biliary Tract Cancers Pipeline Report

• DelveInsight’s Biliary Tract Cancers pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Biliary Tract Cancers treatment.
• The leading companies working in the Biliary Tract Cancers market include Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited, and others.
• Promising Biliary Tract Cancers Pipeline Therapies in the various stages of development include M7824, SMT-NK inj.+Pembrolizumab, Durvalumab, mFOLFOX, ZKAB001 5mg/kg, Capecitabine, RC48-ADC, Atezolizumab, Bevacizumab, Lenvatinib, MRG003, Gemcitabine, Cisplatin, and others.
• November 2023: AstraZeneca announced a study of Phase 2 clinical trials for AZD5305, Durvalumab, Capecitabine, and Volrustomig. This Phase II, open-label, uncontrolled, multicentre study evaluating the efficacy and safety of Dato-DXd as monotherapy (MONO) and in combination with anticancer agents (COMBO) in various advanced solid tumour types. This study has a modular design, as such a master protocol with independent substudies enables simultaneous evaluation of the safety profile, recommended Phase II dose (RP2D), and efficacy of Dato-DXd in multiple disease populations and treatment combinations. This study will evaluate various solid tumour types, including endometrial cancer (Substudy 1), gastric cancer (Substudy 2), metastatic castration-resistant prostate cancer (mCRPC) (Substudy 3), ovarian cancer (Substudy 4), colorectal cancer (CRC) (Substudy 5), urothelial cancer (Substudy 6) and biliary tract cancer (Substudy 7) in the advanced or metastatic setting. Within each substudy, Dato-DXd will be evaluated as monotherapy (for all substudies except Substudy 2 (Gastric Cancer) and Substudy 6 (Urothelial Cancer) and in combination with approved or novel anticancer agents that may be active in the tumour type being evaluated (for all substudies except Substudy 7). 
• November 2023: Bristol-Myers Squibb announced a study of Phase 1 & 2 clinical trials for BMS-986466, Adagrasib and Cetuximab. The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).

Request a sample and discover the recent advances in Biliary Tract Cancers Treatment Drugs @ Biliary Tract Cancers Pipeline Report

The Biliary Tract Cancers pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Biliary Tract Cancers drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Biliary Tract Cancers clinical trial landscape.

Biliary Tract Cancers Overview

Biliary tract cancer is a cancer that forms in the cells of the bile ducts, gallbladder or ampulla of Vater. Cancer of the bile ducts is called cholangiocarcinoma and is classified depending on which part of the bile duct the cancer develops into intrahepatic (affects bile ducts within the liver), hilar (occurs at the junction of the left and right hepatic ducts) and extrahepatic (affects the common bile duct outside the liver) sharing different genetic, risk factors and clinical presentation.

Find out more about Biliary Tract Cancers Treatment Drugs @ Drugs for Biliary Tract Cancers Treatment

Biliary Tract Cancers Emerging Drugs Profile

• MRG 002: Miracogen
• Disitamab vedotin: Yantai Rongchang Pharmaceutical
• Envafolimab: Alphamab Oncology
• DKN-01: Leap Therapeutics

Biliary Tract Cancers Pipeline Therapeutics Assessment

The Biliary Tract Cancers pipeline report proffers an integral view of the Biliary Tract Cancers emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

DelveInsight’s Biliary Tract Cancers Pipeline report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Biliary Tract Cancers Pipeline Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Learn more about the emerging Biliary Tract Cancers Pipeline Therapies @ Biliary Tract Cancers Clinical Trials Assessment

Scope of the Biliary Tract Cancers Pipeline Report

• Coverage- Global
• Biliary Tract Cancers Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Biliary Tract Cancers Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited, and others.
• Biliary Tract Cancers Pipeline Therapies- M7824, SMT-NK inj.+Pembrolizumab, Durvalumab, mFOLFOX, ZKAB001 5mg/kg, Capecitabine, RC48-ADC, Atezolizumab, Bevacizumab, Lenvatinib, MRG003, Gemcitabine, Cisplatin, and others.

Dive deep into rich insights for new drugs for Biliary Tract Cancers Treatment, Visit @ Biliary Tract Cancers Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Biliary Tract Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Biliary Tract Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Envafolimab: Alphamab Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. SMT-NK: SMT bio Co., Ltd.
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. HA121-28: CSPC ZhongQi Pharmaceutical Technology
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. ZKAB001: Lee’s Pharmaceutical Limited
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Biliary Tract Cancer Key Companies
24. Biliary Tract Cancer Key Products
25. Biliary Tract Cancer- Unmet Needs
26. Biliary Tract Cancer- Market Drivers and Barriers
27. Biliary Tract Cancer- Future Perspectives and Conclusion
28. Biliary Tract Cancer Analyst Views
29. Biliary Tract Cancer Key Companies
30. Appendix

For further information on the Biliary Tract Cancers Pipeline therapeutics, reach out to Biliary Tract Cancers Unmet Needs and Analyst Views 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market